RxDoctor Payments DataLook up a doctor →

Sherri Cheek, APRN

Nurse Practitioner · Anderson, SCNPI 1922027234

Payments from drug & device makers

$8,314in general payments, 2019–2025

Across 463 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$919
  • Boston Scientific$889
  • Novartis$799
  • Abbott$793
  • Johnson & Johnson$650
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$467
  • plus $4K from 32 others

What the payments were for

  • Food & beverage$8,22599%
  • Education$891%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,314 in reported general payments places this provider in the 95th percentile of 1,346 nurse practitioner providers in South Carolina.

See all nurse practitioner providers in South Carolina

Medicare billing

Part B allowed, 2024
$33,611
Medicare patients
274
Services billed
429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban292$315,615
EntrestoSacubitril/Valsartan50$68,058
XareltoRivaroxaban45$54,232
Repatha SureclickEvolocumab35$34,716
JardianceEmpagliflozin29$26,858
FarxigaDapagliflozin Propanediol22$19,043
BrilintaTicagrelor27$14,140
Ranolazine ErRanolazine42$3,755
Valsartan130$2,650
Diltiazem 12hr ErDiltiazem Hcl20$2,511
Prasugrel Hcl59$2,214
Metoprolol Succinate189$2,016
Diltiazem 24hr Er (Cd)Diltiazem Hcl44$1,712
Atorvastatin Calcium200$1,563
Carvedilol243$1,546

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$391$315,615292 claims
NovartisEntresto$799$68,05850 claims
Johnson & JohnsonXarelto$650$54,23245 claims
AstraZenecaFarxiga, Brilinta$159$33,18349 claims
Boehringer IngelheimJardiance$150$26,85829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,346 nurse practitioner providers in South Carolina.

Other nurse practitioner in Anderson

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →